Analytica's [ALT] innovative capital raising in the short term should be premised on a key goal to develop PeriCoach to not only extend the company’s leadership and also open additional higher-value markets, but importantly to "...increase the opportunity to partner with multinational medical device companies." [Extract from ALT's Q'tly Cashflow Report dated 29/1/16.]
To: Geoff Daly: Please inform the market asap of progress on increasing that opportunity. How far away is the strategic partner outcome that ALT needs to maximise the commercial success of its leading PeriCoach system?
ALT Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
